ArticleNeurochemical research2026
YY1 Transcriptionally Activates USP19 to Mediate TRAF6 Deubiquitination to Promote Microglial Inflammation and M1 Polarization in Depression Development.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathophysiology of depression is associated with inflammation. This study aims to investigate the mechanism by which Yin Yang 1 (YY1) participates in microglial inflammatory activation and M1 polarization in depression. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to quantify Tumor Necrosis Factor Receptor-Associated Factor 6 (TRAF6) mRNA in serum from depressed patients and healthy controls. A chronic unpredictable mild stress (CUMS) depression mouse model was established, and proteins were detected by Western blot (WB). Receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic value of TRAF6 for depression. Depressive-like behaviors were assessed by behavioral tests. Inflammatory factors were detected via Enzyme-linked immunosorbent assay (ELISA), M1 polarization markers were analyzed via flow cytometry, and WB, respectively. CHX stability and WB-based ubiquitination assays were used to examine the regulatory effect of Ubiquitin-Specific Protease 19 (USP19) on TRAF6 ubiquitination. Chromatin immunoprecipitation (ChIP) and luciferase reporter assays were conducted to verify the transcriptional activation effect of YY1 on USP19. TRAF6 was highly expressed in patient serum and mouse hippocampi, with potential diagnostic value for depression. Silencing TRAF6 improved depressive-like behaviors and reduced inflammation. USP19 was highly expressed in mouse hippocampi, and stabilized TRAF6 via deubiquitination. TRAF6 overexpression reversed inflammation and M1 polarization inhibition from USP19 silencing. YY1 was also highly expressed in mouse hippocampi and activated USP19 transcription. USP19 overexpression reversed the inhibition from YY1 silencing. YY1 activates USP19 to promote TRAF6 deubiquitination and its stabilization, thereby enhancing microglial inflammation and M1 polarization that exacerbates depression progression. This axis may provide a novel direction for depression diagnosis and treatment.
Indexed as
Identifiers
41882442What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.